Advertisement

Pituitary

, Volume 21, Issue 1, pp 65–75 | Cite as

Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study

  • Vivien Bonert
  • John Carmichael
  • Zengru Wu
  • James Mirocha
  • Daniel A. Perez
  • Nigel J. Clarke
  • Richard E. Reitz
  • Michael J. McPhaul
  • Adam Mamelak
Article

Abstract

Purpose

Measuring IGF-1, a biomarker for GH activity, is critical to evaluating disordered hypothalamic-pituitary GH axis. Inconsistent IGF-1 measurements among different immunoassays are well documented. We switched from Immulite 2000 immunoassay to narrow-mass-extraction, high-resolution liquid chromatography mass-spectrometry (LC-MS) compliant with recent consensus recommendations on assay standardization. Comparability of these two assays in patients with pituitary disease in a clinical practice setting is not known. We sought to compare IGF-1 levels on Immulite 2000 and LC-MS in samples from naïve and treated patients with secretory and non-secretory pituitary masses.

Methods

We prospectively collected serum samples from 101 patients treated at the Cedars-Sinai Pituitary Center between February 2012 and March 2014. We intentionally recruited more patients with acromegaly or GH deficiency to ensure a clinically representative cohort. Samples were classified as in or out of the respective reference ranges. Bland–Altman analysis was used to assess agreement between assays.

Results

Twenty-four percent of samples were classified differently as below, in, or above range. Agreement between the assays was poor overall, with a significant bias for immunoassay reporting higher values than LC-MS. This pattern was also observed in patients with acromegaly and those with ≥ 2 pituitary hormone deficiencies.

Conclusions

IGF-1 results may differ after switching from an older immunoassay to a consensus-compliant assay such as LC-MS. Clinicians should consider the potential impact of assay switching before altering treatment due to discrepant results, particularly in patients monitored over time, such as those with acromegaly and GH deficiency.

Keywords

Insulin-like growth factor Pituitary disease Mass spectrometry Immunoassay 

Notes

Acknowledgements

The authors thank Dr. Michael P. Caulfield (Quest Diagnostics) for edits and manuscript discussion and Ms. Shira Berman (Cedars-Sinai Medical Center) for manuscript preparation.

Funding

Support was provided by the Doris Factor Molecular Endocrinology Laboratory at Cedars-Sinai Medical Center. Assays were performed by Quest Diagnostics, Inc. The funding sources had no role in study design, data analysis, or decision to publish.

Compliance with ethical standards

Conflict of interest

Vivien Bonert declares that she has no conflict of interest. John Carmichael declares that he has no conflict of interest. Zengru Wu is an employee of Quest Diagnostics, Inc. James Mirocha declares that he has no conflict of interest. Daniel Perez declares that he has no conflict of interest. Nigel Clarke is an employee of Quest Diagnostics, Inc. Richard Reitz is an employee of Quest Diagnostics, Inc. Michael McPhaul is an employee of Quest Diagnostics, Inc. Adam Mamelak declares that he has no conflict of interest.

References

  1. 1.
    Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355(24):2558–2573CrossRefPubMedGoogle Scholar
  2. 2.
    Clemmons DR (2006) Clinical utility of measurements of insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2(8):436–446.  https://doi.org/10.1038/ncpendmet0244 CrossRefPubMedGoogle Scholar
  3. 3.
    Baumann GP (2012) Growth hormone doping in sports: a critical review of use and detection strategies. Endocr Rev 33(2):155–186.  https://doi.org/10.1210/er.2011-1035 CrossRefPubMedGoogle Scholar
  4. 4.
    Ho KK, Nelson AE (2011) Growth hormone in sports: detecting the doped or duped. Horm Res Paediatr 76(Suppl 1):84–90.  https://doi.org/10.1159/000329185 CrossRefPubMedGoogle Scholar
  5. 5.
    Brabant G, von zur Muhlen A, Wuster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthen L, Saller B, Mattsson A, Wilde J, Schemer R, Kann P (2003) Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 60(2):53–60PubMedGoogle Scholar
  6. 6.
    Frystyk J, Freda P, Clemmons DR (2010) The current status of IGF-I assays: a 2009 update. Growth Horm IGF Res 20(1):8–18.  https://doi.org/10.1016/j.ghir.2009.09.004 CrossRefPubMedGoogle Scholar
  7. 7.
    Bidlingmaier M (2009) Pitfalls of insulin-like growth factor I assays. Horm Res 71(Suppl 1):30–33.  https://doi.org/10.1159/000178034 PubMedGoogle Scholar
  8. 8.
    Clemmons DR (2011) Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 57(4):555–559.  https://doi.org/10.1373/clinchem.2010.150631 CrossRefPubMedGoogle Scholar
  9. 9.
    Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ (2007) Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 67(1):65–70.  https://doi.org/10.1111/j.1365-2265.2007.02836.x CrossRefGoogle Scholar
  10. 10.
    Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J, Korner A, Obermayer-Pietsch B, Hubener C, Dahlgren J, Frystyk J, Pfeiffer AF, Doering A, Bielohuby M, Wallaschofski H, Arafat AM (2014) Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab 99(5):1712–1721.  https://doi.org/10.1210/jc.2013-3059 CrossRefPubMedGoogle Scholar
  11. 11.
    Chanson P, Arnoux A, Mavromati M, Brailly-Tabard S, Massart C, Young J, Piketty ML, Souberbielle JC, Investigators V (2016) Reference values for IGF-I serum concentrations: comparison of six immunoassays. J Clin Endocrinol Metab 101(9):3450–3458.  https://doi.org/10.1210/jc.2016-1257 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Burns C, Rigsby P, Moore M, Rafferty B (2009) The first international standard for insulin-like growth factor-1 (IGF-1) for immunoassay: preparation and calibration in an international collaborative study. Growth Horm IGF Res 19(5):457–462.  https://doi.org/10.1016/j.ghir.2009.02.002 CrossRefPubMedGoogle Scholar
  13. 13.
    Kay R, Halsall DJ, Annamalai AK, Kandasamy N, Taylor K, Fenwick S, Webb A, Wark G, Pleasance S, Gurnell M (2013) A novel mass spectrometry-based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly. Clin Endocrinol (Oxf) 78(3):424–430.  https://doi.org/10.1111/cen.12085 CrossRefGoogle Scholar
  14. 14.
    Bystrom CE, Sheng S, Clarke NJ (2011) Narrow mass extraction of time-of-flight data for quantitative analysis of proteins: determination of insulin-like growth factor-1. Anal Chem 83(23):9005–9010.  https://doi.org/10.1021/ac201800g CrossRefPubMedGoogle Scholar
  15. 15.
    Bystrom C, Sheng S, Zhang K, Caulfield M, Clarke NJ, Reitz R (2012) Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry. PLoS ONE 7(9):e43457.  https://doi.org/10.1371/journal.pone.0043457 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Arsene CG, Kratzsch J, Henrion A (2014) Mass spectrometry: an alternative in growth hormone measurement. Bioanalysis 6(18):2391–2402.  https://doi.org/10.4155/bio.14.196 CrossRefPubMedGoogle Scholar
  17. 17.
    Cox HD, Lopes F, Woldemariam GA, Becker JO, Parkin MC, Thomas A, Butch AW, Cowan DA, Thevis M, Bowers LD, Hoofnagle AN (2014) Interlaboratory agreement of insulin-like growth factor 1 concentrations measured by mass spectrometry. Clin Chem 60(3):541–548.  https://doi.org/10.1373/clinchem.2013.208538 CrossRefPubMedGoogle Scholar
  18. 18.
    Hoofnagle AN, Wener MH (2009) The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 347(1–2):3–11.  https://doi.org/10.1016/j.jim.2009.06.003 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Monaghan PJ, Keevil BG, Trainer PJ (2013) The use of mass spectrometry to improve the diagnosis and the management of the HPA axis. Rev Endocr Metab Disord 14(2):143–157.  https://doi.org/10.1007/s11154-013-9240-1 CrossRefPubMedGoogle Scholar
  20. 20.
    IMMULITE® (2005) 2000 IGF-I [package insert]. In: Diagnostic products corporation. IMMULITE®, Los AngelesGoogle Scholar
  21. 21.
    Elmlinger MW, Kuhnel W, Weber MM, Ranke MB (2004) Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 42(6):654–664.  https://doi.org/10.1515/CCLM.2004.112 CrossRefPubMedGoogle Scholar
  22. 22.
    Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine S (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951.  https://doi.org/10.1210/jc.2014-2700 CrossRefPubMedGoogle Scholar
  23. 23.
    Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML, Endocrine S (2011) Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(6):1587–1609.  https://doi.org/10.1210/jc.2011-0179 CrossRefPubMedGoogle Scholar
  24. 24.
    Toogood AA, Beardwell CG, Shalet SM (1994) The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism. Clin Endocrinol (Oxf) 41(4):511–516CrossRefGoogle Scholar
  25. 25.
    Granada ML, Ulied A, Casanueva FF, Pico A, Lucas T, Torres E, Sanmarti A (2008) Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population. Clin Endocrinol (Oxf) 68(6):942–950.  https://doi.org/10.1111/j.1365-2265.2007.03120.x CrossRefGoogle Scholar
  26. 26.
    Krebs A, Wallaschofski H, Spilcke-Liss E, Kohlmann T, Brabant G, Volzke H, Nauck M (2008) Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population. Clin Chem Lab Med 46(12):1776–1783.  https://doi.org/10.1515/CCLM.2008.349 CrossRefPubMedGoogle Scholar
  27. 27.
    Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S (2014) Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10(4):243–248.  https://doi.org/10.1038/nrendo.2014.21 CrossRefPubMedGoogle Scholar
  28. 28.
    Yuen KC, Tritos NA, Samson SL, Hoffman AR, Katznelson L (2016) American association of clinical endocrinologists and american college of endocrinology disease state clinical review: update on growth hormone stimulation testing and proposed revised cut-point for the glucagon stimulation test in the diagnosis of adult growth hormone deficiency. Endocr Pract 22(10):1235–1244.  https://doi.org/10.4158/EP161407.DSCR CrossRefPubMedGoogle Scholar
  29. 29.
    Hines J, Milosevic D, Ketha H, Taylor R, Algeciras-Schimnich A, Grebe SK, Singh RJ (2015) Detection of IGF-1 protein variants by use of LC-MS with high-resolution accurate mass in routine clinical analysis. Clin Chem 61(7):990–991.  https://doi.org/10.1373/clinchem.2014.234799 CrossRefPubMedGoogle Scholar
  30. 30.
    Wu Z, Sanders HR, Clarke NJ, Caulfield MP, Reitz RE, McPhaul MJ (2016) Identification of circulating IGF-1 polymorphisms by high resolution LC-MS. In: 98th Annual Meeting of the Endocrine Society, Boston, Massachusetts, April 1–4, p. Poster SAT 017Google Scholar
  31. 31.
    Algeciras-Schimnich A, Bruns DE, Boyd JC, Bryant SC, La Fortune KA, Grebe SK (2013) Failure of current laboratory protocols to detect lot-to-lot reagent differences: findings and possible solutions. Clin Chem 59(8):1187–1194.  https://doi.org/10.1373/clinchem.2013.205070 CrossRefPubMedGoogle Scholar
  32. 32.
    Varewijck AJ, Lamberts SW, van der Lely AJ, Neggers SJ, Hofland LJ, Janssen JA (2015) The introduction of the IDS-iSYS total IGF-1 assay may have far-reaching consequences for diagnosis and treatment of GH deficiency. J Clin Endocrinol Metab 100(1):309–316.  https://doi.org/10.1210/jc.2014-2558 CrossRefPubMedGoogle Scholar
  33. 33.
    Vogeser M, Seger C (2010) Pitfalls associated with the use of liquid chromatography-tandem mass spectrometry in the clinical laboratory. Clin Chem 56(8):1234–1244.  https://doi.org/10.1373/clinchem.2009.138602 CrossRefPubMedGoogle Scholar
  34. 34.
    Yuen KC, Cook DM, Sahasranam P, Patel P, Ghods DE, Shahinian HK, Friedman TC (2008) Prevalence of GH and other anterior pituitary hormone deficiencies in adults with nonsecreting pituitary microadenomas and normal serum IGF-1 levels. Clin Endocrinol (Oxf) 69(2):292–298.  https://doi.org/10.1111/j.1365-2265.2008.03201.x CrossRefGoogle Scholar
  35. 35.
    Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ (2002) Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 87(2):477–485CrossRefPubMedGoogle Scholar
  36. 36.
    Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML (1989) Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med 70(262):145–160PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  • Vivien Bonert
    • 1
  • John Carmichael
    • 1
  • Zengru Wu
    • 2
  • James Mirocha
    • 1
  • Daniel A. Perez
    • 1
  • Nigel J. Clarke
    • 2
  • Richard E. Reitz
    • 2
  • Michael J. McPhaul
    • 2
  • Adam Mamelak
    • 1
  1. 1.Pituitary Center, Department of MedicineCedars-Sinai Medical CenterLos AngelesUSA
  2. 2.Quest Diagnostics, Inc.San Juan CapistranoUSA

Personalised recommendations